Forest Laboratories (NYSE: FRX) has taken a big step toward approval for a combination treatment to battle Alzheimer's dementia. The company announced that it, together with privately held Adamas Pharmaceuticals, has submitted a New Drug Application to the Food and Drug Administration for a fixed-dose combination of memantine HCl extended release, and donepezil HCl. The combination is to be used to treat of patients with moderate to severe Alzheimer's dementia.

The blended medication takes the form of an oral capsule that is administered once daily. For patients who have difficulty swallowing, the capsules can be opened and the contents sprinkled on soft food.

Last month, Forest signed an agreement to be acquired by Actavis (NYSE:AGN), for a combination of cash and equity totaling roughly $25 billion, or $89.48 per share. Today, the stock closed at $99.36. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.